OncoMatch/Clinical Trials/NCT06241755
Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Is NCT06241755 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including BCG for Therapeutic Use and BCG for Therapeutic Use for non-muscle invasive bladder cancer.
Treatment: BCG for Therapeutic Use · BCG for Therapeutic Use — A phase III multi-center randomized, double-blind and positive-controlled clinical trial for evaluating the efficacy and safety of BCG for Therapeutic Use（BCG） in the prevention of postoperative recurrence of medium/high-risk non-muscle invasive bladder cancer (NMIBC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Urothelial Carcinoma
Disease stage
Required: Stage TIS
Excluded: Stage MUSCLE INVASIVE, FOCAL ADVANCED, METASTATIC MUSCULAR INFILTRATION
Grade: G3 (advanced grade) tumor, except for simple in situ tumor
medium/high-risk non-muscle invasive urothelial bladder cancer (T1/Ta/Tis)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: transurethral resection of bladder tumor (TURBt)
After a thorough TURBt, all tumors should be grossly invisible. Patients requiring a second procedure are also eligible for inclusion.
Cannot have received: BCG bladder instillation
A previous history of never receiving any therapy of BCG bladder instillation
Lab requirements
Blood counts
ANC ≥1500/mm3 or ≥1.5×10^9/L; platelet ≥100000/mm3 or 100×10^9/L; hemoglobin ≥9 g/dL
Kidney function
estimated creatinine clearance ≥50 mL/min according to the formula of Cockcroft-Gault
Liver function
total serum bilirubin ≤1.5× ULN; for subjects with Gilbert syndrome total serum bilirubin <3×ULN; AST/ALT ≤2.5×ULN
Clinical laboratory tests fulfilling the following features: ... see above
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06241755 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior BCG bladder instillation disqualifies patients from enrollment.
What disease stage is eligible?
Stage TIS is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages